Literature DB >> 18761506

From Lydia Pinkham to Queen Levitra: direct-to-consumer advertising and medicalisation.

Peter Conrad1, Valerie Leiter.   

Abstract

The medicalisation of life problems has been occurring for well over a century and has increased over the past 30 years, with the engines of medicalisation shifting to biotechnology, managed care, and consumers. This paper examines one strand of medicalisation during the last century: direct-to-consumer advertising (DTCA) of pharmaceuticals. In particular, it examines the roles that physicians and the Food and Drug Administration (FDA) have played in regulating DTCA in the US. Two advertising exemplars, the late 19(th) century Lydia E. Pinkham's Vegetable Compound (for 'women's complaints') and contemporary Levitra (for erectile dysfunction) are used to examine the parallels between the patent medicine era and the DTCA era. DTCA re-establishes the direct and independent relationship between drug companies and consumers that existed in the late 19(th) century, encouraging self-diagnosis and requests for specific drugs. The extravagant claims of Lydia Pinkham's day are constrained by laws, but modern-day advertising is more subtle and sophisticated. DTCA has facilitated the impact of the pharmaceutical industry and consumers in becoming more important forces in medicalisation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18761506     DOI: 10.1111/j.1467-9566.2008.01092.x

Source DB:  PubMed          Journal:  Sociol Health Illn        ISSN: 0141-9889


  3 in total

1.  Chronic homework in emerging borderlands of healthcare.

Authors:  Cheryl Mattingly; Lone Grøn; Lotte Meinert
Journal:  Cult Med Psychiatry       Date:  2011-09

2.  Visualizing Risk: Images, Risk and Fear in a Health Campaign.

Authors:  Jessica Kuperavage
Journal:  J Med Humanit       Date:  2017-06

3.  Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities.

Authors:  Jill A Fisher; Marci D Cottingham; Corey A Kalbaugh
Journal:  Soc Sci Med       Date:  2014-08-19       Impact factor: 4.634

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.